Lack of Zika virus antibody response in confirmed patients in non-endemic countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F18%3A43889468" target="_blank" >RIV/60162694:G44__/18:43889468 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.journalofclinicalvirology.com/article/S1386-6532(17)30346-3/pdf" target="_blank" >http://www.journalofclinicalvirology.com/article/S1386-6532(17)30346-3/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jcv.2017.12.007" target="_blank" >10.1016/j.jcv.2017.12.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lack of Zika virus antibody response in confirmed patients in non-endemic countries

Popis výsledku v původním jazyce

Zika virus (ZIKV) has spread in the last 2 years throughout America and South-Eastern Asia causing a widespread epidemic. Detection of ZIKV RNA in body fluids confirms ZIKV infection, however ZIKV antibody testing is much more complex due to possible cross-reactivity with closely related flaviviruses. From December 2015 to February 2017, 401 patients from eight reference laboratories in the Czech Republic, Israel, Italy, the Netherlands, Romania, Slovenia, and the United Kingdom had been confirmed for ZIKV infection by detection of ZIKV RNA in body fluids. Of these 401 patients, 148 were negative for ZIKV directed against IgM and IgG in serum collected at the time of PCR-positivity as tested by ELISA (7 laboratories, Euroimmun, Lübeck, Germany) or IFA and ELISA (2 laboratories, Euroimmun, Lübeck, Germany). For 80 of these 148 seronegative confirmed patients a second, follow-up serum sample was available. Altogether, 5 of these 80 patients remained without seroconversion in consecutive samples for ZIKV antibodies tested by ELISA and virus neutralization (VNT). The acute samples of these 5 patients were re-extracted and retested from original material which confirmed the presence of ZIKV RNA. Material from patients 1 and 2 were sequenced. Ideally, each of the samples from the 5 patients would also have been tested in at least one of the other laboratories, but because of insufficient clinical material, this wasn’t possible. Most importantly, none of the sero-negative patients had any indication of immune-deficiency. Two patients were pregnant.

Název v anglickém jazyce

Lack of Zika virus antibody response in confirmed patients in non-endemic countries

Popis výsledku anglicky

Zika virus (ZIKV) has spread in the last 2 years throughout America and South-Eastern Asia causing a widespread epidemic. Detection of ZIKV RNA in body fluids confirms ZIKV infection, however ZIKV antibody testing is much more complex due to possible cross-reactivity with closely related flaviviruses. From December 2015 to February 2017, 401 patients from eight reference laboratories in the Czech Republic, Israel, Italy, the Netherlands, Romania, Slovenia, and the United Kingdom had been confirmed for ZIKV infection by detection of ZIKV RNA in body fluids. Of these 401 patients, 148 were negative for ZIKV directed against IgM and IgG in serum collected at the time of PCR-positivity as tested by ELISA (7 laboratories, Euroimmun, Lübeck, Germany) or IFA and ELISA (2 laboratories, Euroimmun, Lübeck, Germany). For 80 of these 148 seronegative confirmed patients a second, follow-up serum sample was available. Altogether, 5 of these 80 patients remained without seroconversion in consecutive samples for ZIKV antibodies tested by ELISA and virus neutralization (VNT). The acute samples of these 5 patients were re-extracted and retested from original material which confirmed the presence of ZIKV RNA. Material from patients 1 and 2 were sequenced. Ideally, each of the samples from the 5 patients would also have been tested in at least one of the other laboratories, but because of insufficient clinical material, this wasn’t possible. Most importantly, none of the sero-negative patients had any indication of immune-deficiency. Two patients were pregnant.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Virology

ISSN

1386-6532

e-ISSN

—

Svazek periodika

99-100

Číslo periodika v rámci svazku

February–March

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

31-34

Kód UT WoS článku

000425747400006

EID výsledku v databázi Scopus

2-s2.0-85039698991